Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-16: Adagrasib + Palbociclib in Advanced Solid Tumors
NCT05178888Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adagrasib in solid tumor (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Number of patients with treatment emergent adverse events at 24 months, Pharmacokinetics of the combination regimen at 24 months and 2 more. Started Jan 2022; status: completed.
02
Drugs
adagrasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05178888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178888.